BiotechTube
Home/Pipeline/Psi-GAD

Psi-GAD

Generalized Anxiety Disorder (GAD)

Phase 2Active - Trial ongoingACTRN12623000526673

Key Facts

Indication
Generalized Anxiety Disorder (GAD)
Phase
Phase 2
Status
Active - Trial ongoing
Company
Incannex Healthcare

About Incannex Healthcare

Incannex Healthcare is a clinical-stage biotech focused on developing proprietary cannabinoid and psychedelic-based therapies for conditions with high unmet need, including sleep apnea and anxiety disorders. The company has progressed its lead asset, IHL-42X for OSA, into pivotal Phase 2/3 trials and is advancing a psilocybin program for GAD. Its strategy centers on securing intellectual property around novel formulations and treatment protocols to build a valuable clinical pipeline, funded through its dual listing on the ASX and NASDAQ.

View full company profile

Therapeutic Areas

Sleep DisordersPsychiatryInflammatory Diseases

Other Generalized Anxiety Disorder (GAD) Drugs

DrugCompanyPhase
CTx-2103Cingulate TherapeuticsPhase 2
NTX-1955NewleosPhase 1b
Luvesilocin (RE104)Reunion NeurosciencePre-clinical/Planned
DT120Definium TherapeuticsPhase 3
HLP004Helus PharmaPhase 2
CYB004Helus PharmaPhase 2
BNC210Neuphoria TherapeuticsPhase 2